F5 Gene: History
View Latest Version
Please note this is an old version of this entry, which may differ significantly from the current revision.
Subjects: Genetics & Heredity
Contributor:
Vivi Li

Coagulation factor V

  • genes

1. Normal Function

The F5 gene provides instructions for making a protein called coagulation factor V. Coagulation factors are a group of related proteins that make up the coagulation system, a series of chemical reactions that form blood clots. After an injury, clots seal off blood vessels to stop bleeding and trigger blood vessel repair.

The factor V protein is made primarily by cells in the liver. The protein circulates in the bloodstream in an inactive form until the coagulation system is activated by an injury that damages blood vessels. When coagulation factor V is activated, it interacts with coagulation factor X. The active forms of these two coagulation factors (written as factor Va and factor Xa, respectively) form a complex that converts an important coagulation protein called prothrombin to its active form, thrombin. Thrombin then converts a protein called fibrinogen into fibrin, which is the material that forms the clot.

Coagulation factor V has another role in regulating the coagulation system through its interaction with activated protein C (APC). APC normally inactivates coagulation factor V by cutting (cleaving) it at specific sites. This inactivation slows down the clotting process and prevents clots from growing too large. When coagulation factor V is cleaved at a particular site (protein position 506), it can work with APC to inactivate factor VIIIa, which is another protein that is essential for normal blood clotting.

2. Health Conditions Related to Genetic Changes

2.1 Factor V Deficiency

At least 100 mutations in the F5 gene have been found to cause a rare bleeding disorder called factor V deficiency. These mutations prevent the production of functional coagulation factor V or significantly reduce the amount of the protein in the bloodstream. People with this condition typically have less than 10 percent of normal levels of coagulation factor V in their blood; the most severely affected individuals have less than 1 percent. A reduced amount of functional factor V prevents blood from clotting normally, causing episodes of abnormal bleeding that can be severe. Factor V deficiency results from mutations in both copies of the F5 gene, although some people with a mutation in a single copy of the gene have mild bleeding problems.

2.2 Factor V Leiden Thrombophilia

Factor V Leiden is the name of a specific mutation in the F5 gene. This mutation changes a single protein building block (amino acid) in the factor V protein. Specifically, it replaces the amino acid arginine with the amino acid glutamine at protein position 506 (written as Arg506Gln or R506Q). Because position 506 is one of the sites where APC normally cleaves coagulation factor V, the factor V Leiden mutation slows the rate at which APC inactivates this factor. As a result, both the activated form of coagulation factor V and coagulation factor VIIIa persist longer in circulation, increasing the risk of developing an abnormal blood clot. This tendency to form abnormal clots that can block blood vessels is known as thrombophilia.

The presence of the factor V Leiden mutation in one or both copies of the F5 gene can cause thrombophilia; two copies of the mutation lead to a higher risk of developing abnormal blood clots than a single copy of the mutation.

2.3 Other Disorders

Some people have the factor V Leiden mutation (Arg506Gln) in one copy of the F5 gene and a mutation associated with factor V deficiency in the other copy of the gene in each cell. The factor V Leiden mutation results in the production of an abnormal coagulation factor V protein that is resistant to inactivation by APC, while the other mutation prevents the production of any coagulation factor V protein. This combination of mutations is associated with an increased risk of abnormal blood clots similar to the risk associated with having two copies of the factor V Leiden mutation. This rare condition is known as pseudohomozygous APC resistance or pseudohomozygous factor V Leiden.

The factor V Leiden mutation is involved in some cases of a condition known as Budd-Chiari syndrome. This condition is characterized by a blockage of blood flow from the liver, which can be caused by a blood clot. People with thrombophilia, including that caused by the factor V Leiden mutation, have an increased risk of developing Budd-Chiari syndrome. Signs and symptoms of the syndrome include pain in the abdomen, an abnormally large liver (hepatomegaly), and accumulation of fluid in the lining of the abdomen (ascites).

3. Other Names for This Gene

  • blood coagulation factor V

  • coagulation factor V (proaccelerin, labile factor)

  • factor V

This entry is adapted from the peer-reviewed paper https://medlineplus.gov/genetics/gene/f5

References

  1. Asselta R, Peyvandi F. Factor V deficiency. Semin Thromb Hemost. 2009Jun;35(4):382-9. doi: 10.1055/s-0029-1225760.
  2. Asselta R, Tenchini ML, Duga S. Inherited defects of coagulation factor V: thehemorrhagic side. J Thromb Haemost. 2006 Jan;4(1):26-34. Review.
  3. Brugge JM, Simioni P, Bernardi F, Tormene D, Lunghi B, Tans G, Pagnan A,Rosing J, Castoldi E. Expression of the normal factor V allele modulates the APC resistance phenotype in heterozygous carriers of the factor V Leiden mutation. J Thromb Haemost. 2005 Dec;3(12):2695-702.
  4. Castoldi E, Rosing J. Factor V Leiden: a disorder of factor V anticoagulantfunction. Curr Opin Hematol. 2004 May;11(3):176-81. Review.
  5. Colak Y, Karasu Z, Oruc N, Can C, Balým Z, Akarca U, Gunsar F, Ersoz G, Tokat Y, Batur Y. Hyperhomocysteinaemia and factor V Leiden mutation are associatedwith Budd-Chiari syndrome. Eur J Gastroenterol Hepatol. 2006 Aug;18(8):917-20.
  6. Cutler JA, Patel R, Rangarajan S, Tait RC, Mitchell MJ. Molecularcharacterization of 11 novel mutations in patients with heterozygous andhomozygous FV deficiency. Haemophilia. 2010 Nov;16(6):937-42. doi:10.1111/j.1365-2516.2010.02330.x.
  7. Duga S, Asselta R, Tenchini ML. Coagulation factor V. Int J Biochem Cell Biol.2004 Aug;36(8):1393-9. Review.
  8. Grody WW, Griffin JH, Taylor AK, Korf BR, Heit JA; ACMG Factor V. LeidenWorking Group. American College of Medical Genetics consensus statement on factorV Leiden mutation testing. Genet Med. 2001 Mar-Apr;3(2):139-48.
  9. Janssen HL, Meinardi JR, Vleggaar FP, van Uum SH, Haagsma EB, van Der Meer FJ,van Hattum J, Chamuleau RA, Adang RP, Vandenbroucke JP, van Hoek B, Rosendaal FR.Factor V Leiden mutation, prothrombin gene mutation, and deficiencies incoagulation inhibitors associated with Budd-Chiari syndrome and portal veinthrombosis: results of a case-control study. Blood. 2000 Oct 1;96(7):2364-8.
  10. Lak M, Sharifian R, Peyvandi F, Mannucci PM. Symptoms of inherited factor Vdeficiency in 35 Iranian patients. Br J Haematol. 1998 Dec;103(4):1067-9.
  11. Mann KG, Kalafatis M. Factor V: a combination of Dr Jekyll and Mr Hyde. Blood.2003 Jan 1;101(1):20-30.
  12. Nicolaes GA, Dahlbäck B. Factor V and thrombotic disease: description of ajanus-faced protein. Arterioscler Thromb Vasc Biol. 2002 Apr 1;22(4):530-8.Review.
  13. Ornstein DL, Cushman M. Cardiology patient page. Factor V Leiden. Circulation.2003 Apr 22;107(15):e94-7.
  14. Rosendorff A, Dorfman DM. Activated protein C resistance and factor V Leiden: a review. Arch Pathol Lab Med. 2007 Jun;131(6):866-71. Review.
  15. Segers K, Dahlbäck B, Nicolaes GA. Coagulation factor V and thrombophilia:background and mechanisms. Thromb Haemost. 2007 Sep;98(3):530-42. Review.
  16. Vos HL. Inherited defects of coagulation Factor V: the thrombotic side. JThromb Haemost. 2006 Jan;4(1):35-40.
More
©Text is available under the terms and conditions of the Creative Commons-Attribution ShareAlike (CC BY-SA) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
This entry is offline, you can click here to edit this entry!
Feedback